BRICS Nations Strengthen Pharmaceutical Sovereignty Amidst Global Health Imperatives
According to the International Desk of Webangah News Agency, The COVID-19 pandemic underscored the critical importance of robust healthcare systems, indigenous scientific capabilities, and a strong pharmaceutical industry for national resilience and stability. Access to medicines, vaccine production, and advancements in medical technology have increasingly become key components of national security for countries worldwide.
In response, Global South nations are placing significant emphasis on bolstering their internal health and pharmaceutical sectors, with BRICS emerging as a vital platform for scientific cooperation, technology transfer, and joint projects in this domain. The final statement from the 17th BRICS Summit in Rio de Janeiro reaffirmed the commitment to strengthening global health governance through international collaboration and solidarity.
Experts define ‘pharmaceutical sovereignty’ as a nation’s capacity to independently secure essential medicines, produce vaccines, and maintain a skilled healthcare workforce. Margarita Isakova, Head of the International Department of the Pirogov Russian National Research Medical University, highlighted to TV BRICS that vaccine accessibility extends beyond mere availability in healthcare facilities, encompassing affordability for citizens and adequate infrastructure for storage and distribution.
She noted that many Global South countries remain reliant on imports for pharmaceutical raw materials and essential equipment, a dependency that even affects nations with established drug manufacturing lines, rendering their health systems vulnerable to global supply chain disruptions. BRICS member states have consequently made substantial investments in developing their domestic pharmaceutical and vaccine production capacities.
India, recognized as the world’s largest producer of generic drugs, supplies approximately one-fifth of the global market for generics and manufactures nearly 60% of vaccines required by UNICEF. China boasts the largest vaccine production capacity globally and has invested billions in researching and developing next-generation drugs to combat diseases such as influenza, tuberculosis, and dengue fever.
Russia, leveraging its extensive history in virology and epidemiology, has prioritized the development of its pharmaceutical industry. Its ‘Pharma 2030’ strategy aims for domestically produced drugs to constitute around 70% of the national market by the end of the current decade. Brazil stands as a significant pharmaceutical hub in Latin America, investing heavily in vaccine production and tropical disease control, meeting a substantial portion of its biopharmaceutical needs and implementing extensive free vaccination programs.
The United Arab Emirates has emerged as a leading pharmaceutical center in the Middle East, playing a crucial role in regional medical and pharmaceutical product distribution. Egypt’s pharmaceutical industry is the largest in the Middle East and North Africa, fulfilling approximately 90% of the country’s domestic needs. Through its vaccine localization program, the Egyptian government aims to reach an annual vaccine production of 140 million doses by 2030 and export products to over 60 countries.
South Africa possesses one of Africa’s most advanced pharmaceutical industries, with market valuations estimated by experts to exceed $12 billion. In Ethiopia, while a significant portion of medicines are imported, the government is actively pursuing plans to expand domestic production of vaccines and medical equipment. According to the Ministry of Health, local producers now contribute over 44% to the nation’s pharmaceutical needs.
Iran is also recognized as a regional leader in the pharmaceutical sector. Former Iranian Health Minister, Bahram Einollahi, previously stated that Iran is the sole country in the region capable of producing and developing vaccines for diseases like polio, tuberculosis, and cholera, with over 90% of the country’s medicinal needs met through domestic production.
Despite these advancements, experts acknowledge that equitable access to medicines and vaccines remains a significant challenge for Global South nations. Obstacles include intellectual property regimes, the high cost of innovative drugs, and limited financial resources within healthcare systems. Vittoria Davi Marzola, a public health researcher in Brazil, observed that over-reliance on major pharmaceutical companies and restricted global networks can delay access to medicines and exacerbate health inequalities.
She emphasized that scientific and technological cooperation among BRICS members and the activities of the BRICS Vaccine Research and Development Center can help diminish the dependence of Global South nations on external suppliers. The BRICS Vaccine Research and Development Center, established in 2022, now serves as a hub for collaborative research, development, testing, and technology transfer for vaccines and biopharmaceutical products.
Experts believe that fostering these collaborations can transform Global South countries from mere consumers of medicines and vaccines into active participants across the entire value chain, from research and development to production, distribution, and oversight. Sustainable public financing, technology transfer, specialized workforce training, joint procurement, and the development of regional cooperation mechanisms are identified as crucial measures to accelerate the achievement of pharmaceutical sovereignty in these nations. Enhancing pharmaceutical and vaccine-making capacities within BRICS countries is expected not only to bolster their health security but also to contribute to a more balanced global healthcare landscape.
